Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 10;8(10):e011709. doi: 10.1161/JAHA.118.011709

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Quantitative contrast enhancement in relation to positron emission tomography–evidenced metabolic activity. A, Signal‐to‐noise ratio (SNR; left) and contrast‐enhancement heterogeneity (CEH; right) among cardiac mass subgroups partitioned based on diagnostic test interpretation. Note higher SNR for fluorodeoxyglucose (FDG) avid vs nonavid neoplasm (NEO; P=0.004), paralleling higher SNR and CEH for both NEO subtypes vs thrombus (THR; both P<0.001). Data shown as median plus or minus interquartile range. B, Scatter plots demonstrating correlation between SNR and standardized uptake value (SUV) within NEO. Highly mobile lesions excluded from analyses (due to imprecise colocalization). Note significant correlations between magnitude of contrast‐enhancement and FDG avidity (P<0.05).